PDF(Pubmed)
Abstract：
BACKGROUND: Biomarker-informed criteria were proposed for the diagnosis of Alzheimer\'s disease (AD) by the National Institute on Aging and the Alzheimer\'s Association (NIA-AA) in 2011; however, the adequacy of this criteria has not been sufficiently evaluated.
METHODS: ReDeMa (Red de Demencias de Madrid) is a regional cohort of patients attending memory and neurology clinics. Core cerebrospinal fluid biomarkers were obtained, NIA-AA diagnostic criteria were considered, and changes in diagnosis and management were evaluated.
RESULTS: A total of 233 patients were analyzed (mean age 70 years, 50% women, 73% AD). The diagnostic language was modified significantly, with a majority assumption of NIA-AA definitions (69%). Confidence in diagnosis increased from 70% to 92% (p < 0.0005) and management was changed in 71% of patient/caregivers. The influence of neurologist\'s age or expertise on study results was minimal.
CONCLUSIONS: The NIA-AA criteria are adequate and utile for usual practice in memory and neurology clinics, improving diagnostic confidence and significantly modifying patient management.
CONCLUSIONS: Alzheimer\'s disease (AD) cerebrospinal fluid (CSF) biomarkers increase diagnostic certainty regardless of the neurologist.AD CSF biomarkers lead to changes in disease management .Biomarker-enriched, 2011 NIA-AA diagnostic criteria are adequate for usual practice.
METHODS: ReDeMa (Red de Demencias de Madrid) is a regional cohort of patients attending memory and neurology clinics. Core cerebrospinal fluid biomarkers were obtained, NIA-AA diagnostic criteria were considered, and changes in diagnosis and management were evaluated.
RESULTS: A total of 233 patients were analyzed (mean age 70 years, 50% women, 73% AD). The diagnostic language was modified significantly, with a majority assumption of NIA-AA definitions (69%). Confidence in diagnosis increased from 70% to 92% (p < 0.0005) and management was changed in 71% of patient/caregivers. The influence of neurologist\'s age or expertise on study results was minimal.
CONCLUSIONS: The NIA-AA criteria are adequate and utile for usual practice in memory and neurology clinics, improving diagnostic confidence and significantly modifying patient management.
CONCLUSIONS: Alzheimer\'s disease (AD) cerebrospinal fluid (CSF) biomarkers increase diagnostic certainty regardless of the neurologist.AD CSF biomarkers lead to changes in disease management .Biomarker-enriched, 2011 NIA-AA diagnostic criteria are adequate for usual practice.
摘要：
背景：美国国家衰老研究所和阿尔茨海默病协会（NIA-AA）于2011年提出了用于诊断阿尔茨海默病（AD）的生物标记信息标准；但是，该标准的充分性尚未得到充分评估。
方法：ReDeMa(ReddeDemenciasdeMadrid)是在记忆和神经科门诊就诊的区域患者队列。获得核心脑脊液生物标志物，考虑了NIA-AA诊断标准，并评估了诊断和管理方面的变化.
结果：共分析了233例患者（平均年龄70岁，50%的女性,73%AD)。诊断语言被显著修改，大多数假设NIA-AA定义(69%)。对诊断的信心从70％增加到92％（p<0.0005），71％的患者/护理人员的管理发生了变化。神经科医生的年龄或专业知识对研究结果的影响很小。
结论：NIA-AA标准对于记忆和神经病学诊所的常规实践是足够和有用的，提高诊断信心并显著改善患者管理。
结论：阿尔茨海默病（AD）脑脊液（CSF）生物标志物可提高诊断确定性，而与神经科医生无关。ADCSF生物标志物导致疾病管理的变化。富含生物标志物，2011年NIA-AA诊断标准对于常规实践是足够的。
方法：ReDeMa(ReddeDemenciasdeMadrid)是在记忆和神经科门诊就诊的区域患者队列。获得核心脑脊液生物标志物，考虑了NIA-AA诊断标准，并评估了诊断和管理方面的变化.
结果：共分析了233例患者（平均年龄70岁，50%的女性,73%AD)。诊断语言被显著修改，大多数假设NIA-AA定义(69%)。对诊断的信心从70％增加到92％（p<0.0005），71％的患者/护理人员的管理发生了变化。神经科医生的年龄或专业知识对研究结果的影响很小。
结论：NIA-AA标准对于记忆和神经病学诊所的常规实践是足够和有用的，提高诊断信心并显著改善患者管理。
结论：阿尔茨海默病（AD）脑脊液（CSF）生物标志物可提高诊断确定性，而与神经科医生无关。ADCSF生物标志物导致疾病管理的变化。富含生物标志物，2011年NIA-AA诊断标准对于常规实践是足够的。
